Credit Suisse Group Reiterates “$55.00” Price Target for Pfizer (NYSE:PFE)

Credit Suisse Group set a $55.00 price target on Pfizer (NYSE:PFEGet Rating) in a report issued on Wednesday, Borsen Zeitung reports.

Several other research analysts also recently commented on the stock. StockNews.com started coverage on shares of Pfizer in a research report on Wednesday, October 12th. They set a strong-buy rating for the company. JPMorgan Chase & Co. set a $50.00 price objective on shares of Pfizer in a research report on Tuesday, November 1st. Morgan Stanley boosted their price objective on shares of Pfizer from $50.00 to $51.00 and gave the company an equal weight rating in a research report on Wednesday, November 2nd. Wells Fargo & Company lowered their price objective on shares of Pfizer from $55.00 to $54.00 and set an overweight rating for the company in a research report on Wednesday, November 2nd. Finally, Berenberg Bank set a $44.00 target price on shares of Pfizer in a research note on Wednesday, September 14th. Nine investment analysts have rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the company has an average rating of Moderate Buy and a consensus price target of $56.56.

Pfizer Stock Down 0.5 %

Shares of PFE opened at $48.85 on Wednesday. Pfizer has a one year low of $41.44 and a one year high of $61.71. The company has a market cap of $274.21 billion, a P/E ratio of 9.39, a P/E/G ratio of 0.61 and a beta of 0.69. The company has a debt-to-equity ratio of 0.35, a current ratio of 1.59 and a quick ratio of 1.37. The firm has a 50 day simple moving average of $45.42 and a two-hundred day simple moving average of $48.50.

Pfizer Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, December 5th. Investors of record on Friday, November 4th will be issued a $0.40 dividend. The ex-dividend date of this dividend is Thursday, November 3rd. This represents a $1.60 annualized dividend and a yield of 3.28%. Pfizer’s payout ratio is 30.77%.

Hedge Funds Weigh In On Pfizer

Hedge funds and other institutional investors have recently bought and sold shares of the company. JB Capital LLC lifted its holdings in Pfizer by 3.5% in the second quarter. JB Capital LLC now owns 146,908 shares of the biopharmaceutical company’s stock valued at $7,702,000 after buying an additional 5,027 shares during the period. Versor Investments LP lifted its holdings in Pfizer by 59.7% in the second quarter. Versor Investments LP now owns 68,200 shares of the biopharmaceutical company’s stock valued at $3,576,000 after buying an additional 25,500 shares during the period. Foundry Partners LLC lifted its holdings in Pfizer by 10.0% in the second quarter. Foundry Partners LLC now owns 485,705 shares of the biopharmaceutical company’s stock valued at $25,466,000 after buying an additional 44,260 shares during the period. Griffin Asset Management Inc. lifted its holdings in Pfizer by 1.5% in the second quarter. Griffin Asset Management Inc. now owns 72,327 shares of the biopharmaceutical company’s stock valued at $3,792,000 after buying an additional 1,049 shares during the period. Finally, Jmac Enterprises LLC lifted its holdings in Pfizer by 0.8% in the second quarter. Jmac Enterprises LLC now owns 45,389 shares of the biopharmaceutical company’s stock valued at $2,380,000 after buying an additional 377 shares during the period. Institutional investors and hedge funds own 67.90% of the company’s stock.

Pfizer Company Profile

(Get Rating)

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands.

Featured Articles

Analyst Recommendations for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.